SAN FRANCISCO (GenomeWeb) – Illumina expects that business from its clinical customers will soon outpace that from research customers. President and CEO Francis deSouza said during a conference call with investors and analysts this week that clinical and translational customers made up 45 percent of the firm's product shipments in 2017, up from 39 percent in 2016.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.